The SYNERGY bioabsorbable-polymer (BP) drug-eluting stent (DES) showed similar clinical outcomes to durable-polymer (DP) DES in high-risk patients undergoing percutaneous coronary intervention (PCI), according to a substudy of the TWILIGHT trial.
Usman Baber, MD, MS, of the Icahn School of Medicine at Mount Sinai, presented the results of the TWILIGHT-SYNERGY study on behalf of Roxana Mehran, MD, and other TWILIGHT investigators at the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 virtual conference.
|